卡维地洛对慢性心力衰竭患者Th17细胞功能的调节

Th17 Cell Function Regulation by Carvedilol in Patients with Chronic Heart Failure

目的:研究卡维地洛对慢性心力衰竭患者血清Th7细胞功能的影响。方法:48例慢性心力衰竭患者随机分为常规治疗组(23例)和卡维地洛组(25例),另选取20例健康体检者为健康对照组。于治疗前和治疗6个月时检测血清中Th17型细胞因子白介素-17(IL-17)及其相关因子IL-6、IL-23的水平。结果:慢性心力衰竭患者血清中IL-17及IL-6、IL-23水平明显高于健康对照组(P<0.01)。与治疗前相比,治疗6个月后卡维地洛组和常规治疗组患者IL-17及IL-6,IL-23水平均有明显下降(P<0.01),且卡维地洛组上述指标均显著低于常规治疗组(P<0.05)。结论:慢性心力衰竭患者存在Th17细胞功能亢进,卡维地洛可以明显下调Th17细胞功能,该效应可能是卡维地洛改善慢性心力衰竭患者心功能的作用机制之一。

Objective： To evaluate the regulation effect of carvedilol on the function of T-helper 17 （Th17） cells in patients with chronic heart failure （CHF）. Method： 48 CHF patients were enrolled in the study and randomly divided into routine-treated group （ n = 23 ） and carvedilol-treated group. 20 healthy volunteers were recruited in the control group. Blood samples were obtained before and 6 months after routine or carvedilol therapy and serum levels of intedeukin-17 （ IL-17 ） , interleukin-6 （ IL-6 ） and interleukin-23 （IL-23） were measured by ELISA. Result： Serum levels of IL-17, IL-6 and IL-23 were significantly higher in CHF patients than in the controls （P 〈 0. 01 ）. After the therapy,the serum levels of IL-17, IL-6 and IL-23 of CHF patients in the two groups both significantly decreased （P 〈0. 01 ）. However,CHF patents in the carvedilol-treated group showed lower serum levels of eytokines when compared with those in the routine-treated group （ P 〈 0. 05 ）. Conclusion ： Carvedilol could down-regulate the function of Th17 cells in CHF patients which may be the underlying mechanism of its improvement effects on CHF.